Sollpura: Ph III SOLUTION data

Top-line data from the open-label, international Phase III SOLUTION trial in 129 patients showed that oral Sollpura missed the primary endpoint of non-inferiority to oral porcine-derived pancreatic enzyme replacement therapy (PERT) in the change from baseline in CFA following 7 weeks

Read the full 416 word article

User Sign In